enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of "Buy" from Analysts

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) has been given a consensus rating of "Buy" by the ten ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $25.89.

Several equities research analysts have recently issued reports on ENGN shares. UBS Group cut shares of enGene from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $34.00 to $7.00 in a research report on Friday, February 14th. Raymond James started coverage on shares of enGene in a research report on Wednesday, November 27th. They set an "outperform" rating and a $23.00 price objective for the company. HC Wainwright started coverage on shares of enGene in a research report on Monday, December 23rd. They set a "buy" rating and a $25.00 price objective for the company. Citizens Jmp raised shares of enGene to a "strong-buy" rating in a research report on Monday, November 18th. Finally, Piper Sandler started coverage on shares of enGene in a research report on Tuesday. They set an "overweight" rating and a $26.00 price objective for the company.

Institutional Investors Weigh In On enGene

Institutional investors and hedge funds have recently bought and sold shares of the stock. Toronto Dominion Bank purchased a new stake in shares of enGene in the fourth quarter valued at about $97,000. VR Adviser LLC raised its holdings in shares of enGene by 41.5% in the fourth quarter. VR Adviser LLC now owns 5,046,414 shares of the company's stock valued at $33,559,000 after buying an additional 1,480,573 shares during the last quarter. Vestal Point Capital LP purchased a new stake in shares of enGene in the fourth quarter valued at about $2,460,000. Sphera Funds Management LTD. purchased a new stake in shares of enGene in the fourth quarter valued at about $3,724,000. Finally, Point72 Asset Management L.P. raised its holdings in shares of enGene by 84.7% in the fourth quarter. Point72 Asset Management L.P. now owns 1,224,797 shares of the company's stock valued at $8,145,000 after buying an additional 561,797 shares during the last quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Stock Up 2.0 %

Shares of NASDAQ:ENGN traded up $0.12 during trading on Wednesday, hitting $6.24. The company's stock had a trading volume of 83,747 shares, compared to its average volume of 175,557. The business has a 50 day moving average price of $6.77 and a two-hundred day moving average price of $7.19. The company has a market capitalization of $276.07 million, a PE ratio of -10.76 and a beta of -0.65. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $18.40.

enGene (NASDAQ:ENGN - Get Free Report) last posted its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.06. As a group, research analysts expect that enGene will post -1.56 EPS for the current fiscal year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.